CombinatoRx Completes Enrollment In Phase 2B Clinical Trial Of CRx-102 In Knee Osteoarthritis

CombinatoRx, Incorporated (NASDAQ: CRXX) announced that it has completed patient enrollment in COMET-1 (CRx-102 Osteoarthritis Multi-center Evaluation Trial), the Company’s Phase 2b clinical trial designed to evaluate the safety and efficacy of CRx-102 in subjects with symptomatic knee osteoarthritis. The COMET-1 clinical study has been overenrolled, with 279 patients participating.

More: continued here

Filed under: Arthritis on June 1st, 2008